Epigenome wide association study of SNP–CpG interactions on changes in triglyceride levels after pharmaceutical intervention: a GAW20 analysis

Table 3 Summary of CpG results after collapsing using the minimum method

Gene	Chr	# of significant interactions^a(Total)	Significant SNPs with > 1 methods^b	Smallest interaction p value (rs#)	SNPp value^c	SNP location (bp)	# of CpGs within region collapsed
APOA1	11	0 (45)	1	0.292 (rs633389)	0.381	116,667,337	57
APOA5	11	4 (43)	0	0.02564 (rs10488699)	0.00487	116,632,500	80
APOB	2	3 (43)	3	0.00286 (rs693)	0.0851	21,232,195	31
APOC3	11	0 (46)	0	0.111 (rs632153)	0.119	116,710,239	68
BUD13	11	5 (46)	2	0.0252 (rs12279373)	0.0155	116,600,400	63
CETP	16	4 (43)	0	0.0199 (rs247609)	0.984	56,973,461	47
CLIP2	7	1 (16)	1	0.0143 (rs4298392)	0.791	73,862,441	74
DOCK7	1	9 (38)	0	0.0215 (73862441)	0.306	63,049,819	39
FADS1	11	4 (18)	1	0.000440 (rs174534)	0.217	61,549,458	107
FADS2	11	3 (19)	1	0.00314 (rs174534)	0.214	61,549,458	109
FADS3	11	0 (21)	1	0.102 (rs7927548)	0.461	61,690,901	45
GALNT2	1	7 (138)	3	0.00154 (rs10779837)	0.194	230,327,568	96
GCKR	2	1 (9)	0	0.0480 (rs4665383)	0.0490	27,791,555	32
LPL	8	0 (53)	0	0.157 (rs10102876)	0.869	19,779,785	17
MLXIPL	7	0 (10)	1	0.0826 (rs7782054)	0.135	73,028,759	98
OTOR	20	0 (46)	3	0.0510 (rs16998203)	0.792	16,739,519	20
PLTP	20	3 (24)	0	0.0327 (rs11086984)	0.955	44,511,627	91
TRIB1	8	0 (32)	0	0.0802 (rs17663005)	0.798	126,464,388	38

^aWith a significance level of 0.05
^bThe SNP was found to be significant with more than 1CpG collapsing method. Refer to methods section
^cFrom a model with only main effects terms for CpG and SNP (ie, Model 1 without the interaction term)

ISSN: 1753-6561